Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: Systematic review and meta-analysis of randomized controlled trials

Valeria M. Saglimbene, Germaine Wong, Anita van Zwieten, Suetonia C. Palmer, Marinella Ruospo, Patrizia Natale, Katrina Campbell, Armando Teixeira-Pinto, Jonathan C. Craig, Giovanni F.M. Strippoli

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background & aims: Dietary and supplemental long chain omega-3 polyunsaturated fatty acids (n-3 PUFA) have shown vascular benefits for the general population, but effects among people with chronic kidney disease (CKD) are largely uncertain. We aimed to evaluate the effects of n-3 PUFA intake among patients with CKD. Methods: We searched MEDLINE, Embase, and CENTRAL through January 12, 2018. Eligible studies were randomized controlled trials evaluating n-3 PUFA intake (supplementation or dietary) compared with placebo, standard care, or other treatment, on cardiovascular and all-cause mortality, end stage kidney disease (ESKD), acute transplant rejection, and allograft loss. Risks of bias and evidence certainty were assessed using Cochrane and Grading of Recommendations Assessment, Development and Evaluation processes. Results: Sixty trials (4129 participants) were eligible, all of supplementation, with a median follow-up of 6 months. Low to very low certainty evidence suggested that n-3 PUFA supplementation reduced cardiovascular death for participants on hemodialysis (39 events; relative risk (RR) 0.45, 95% confidence interval (CI) 0.23–0.89), prevented ESKD (29 events; RR 0.30, CI 0.09–0.98) in participants with CKD not receiving renal replacement therapy, and made little or no difference in all-cause mortality (215 events; RR 1.05, CI 0.84–1.33), acute transplant rejection (188 events; RR 0.98, CI 0.80–1.21) or allograft loss (39 events; RR 0.98, CI 0.54–1.81]). Risk of bleeding (44 events; RR 1.40, CI 0.78–2.49) and gastrointestinal side-effects (103 events; RR 1.14, CI 0.79–1.67) were uncertain. Conclusions: n-3 PUFA supplementation may reduce cardiovascular mortality in patients on hemodialysis but it is uncertain whether supplementation prevents mortality or ESKD in patients with CKD.

Original languageEnglish
Pages (from-to)358-368
Number of pages11
JournalCLINICAL NUTRITION
Volume39
Issue number2
Early online date14 Mar 2019
DOIs
Publication statusPublished - Feb 2020

Bibliographical note

©2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Keywords

  • CKD
  • Dialysis
  • ESKD
  • Fish oil
  • Kidney transplant
  • Omega 3

Fingerprint Dive into the research topics of 'Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: Systematic review and meta-analysis of randomized controlled trials'. Together they form a unique fingerprint.

  • Cite this

    Saglimbene, V. M., Wong, G., van Zwieten, A., Palmer, S. C., Ruospo, M., Natale, P., Campbell, K., Teixeira-Pinto, A., Craig, J. C., & Strippoli, G. F. M. (2020). Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: Systematic review and meta-analysis of randomized controlled trials. CLINICAL NUTRITION, 39(2), 358-368. https://doi.org/10.1016/j.clnu.2019.02.041